The Emergence of Psilocybin in Psychiatry and Neuroscience
Pharmaceuticals – April 09, 2025
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen, is showing compelling promise in Psychiatry and Medicine. Emerging evidence from clinical trials supports its efficacy for conditions like Major depressive disorder and anxiety. This psychedelic compound, whose therapeutic action involves Neurotransmitter Receptor Influence on Behavior, offers new avenues in Psychology. Advances in Chemical synthesis and alkaloids are vital for broader access. As Psychedelics and Drug Studies progress, careful integration is key to realizing psilocybin's potential.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), and cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, and limited population diversity in clinical trials. Advances in biosynthetic production and optimized psychotherapeutic integration are necessary to ensure scalability and accessibility. Future research should focus on long-term safety, dosing precision, and neurobiological mechanisms to refine its therapeutic applications. This review provides a critical foundation for advancing evidence-based clinical integration of psilocybin.